Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | THRA | P10827 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | TYMS | P04818 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | LIG1 | P18858 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.40 |
| ▸ | GGT1 | P19440 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29531388 | 0.85 | CYP3A4 (0.52) | KDM4EHSD17B10HPGDMAPTTHRB | |
| SCHEMBL5069944 | 0.85 | CYP3A4 (0.52) | KDM4EHSD17B10HPGDMAPTTHRB | |
| Methyl Salicylate Acrylic Ester SCHEMBL1054590 | 0.85 | SLC6A3 (0.61) | KDM4EHSD17B10HPGDMAPTTHRA | |
| SCHEMBL27385335 | 0.85 | HPGD (0.49) | HSD17B10HPGDMAPTALDH1A1TSHR | |
| SCHEMBL8855153 | 0.83 | HSD17B10 (0.56) | KDM4EHSD17B10HPGDMAPTTHRA | |
| SCHEMBL752535 | 0.82 | KDM4E (0.73) | KDM4EHSD17B10HPGDMAPTTHRA | |
| SCHEMBL29378503 | 0.82 | KDM4E (0.73) | KDM4EHSD17B10HPGDMAPTTHRA | |
| SCHEMBL3841280 | 0.81 | THRB (0.56) | KDM4EHSD17B10HPGDMAPTTHRA | |
| SCHEMBL29413361 | 0.81 | THRB (0.56) | KDM4EHSD17B10HPGDMAPTTHRA | |
| SCHEMBL1055222 | 0.81 | TSHR (0.59) | KDM4EHSD17B10HPGDMAPTTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6368615-B1 | POLYMER OF UNSATURATED ESTER OF SALICYLIC ACID | GUTTAG ALVIN (US) | 2002-04-09 | — | — | US | claimed |
| CN-110302062-B | Dental adhesive glass ion water-gate composition with good removability | 株式会社松风 | 2024-06-07 | — | — | CN | disclosed |
| US-7015247-B2 | Ibuprofen-aspirin, hydroxymethylacylfulvene analogs and L-sugar illudin analogs | GUTTAG ALVIN | 2006-03-21 | — | — | US | disclosed |
| US-20030008833-A1 | Ibuprofen-aspirin, hydroxymethylacylfulvene analogs and L-sugar illudin analogs | GUTTAG ALVIN (US) | 2003-01-09 | — | — | US | disclosed |
| US-6436916-B1 | PHENOLIC ESTERS OF IBUPROFEN WITH SALICYLIC ACID OR ITS NONTOXIC SALTS USED AS ANTITUMOR AGENT | GUTTAG ALVIN (US) | 2002-08-20 | — | — | US | disclosed |
| US-20020065254-A1 | Ibuprofen-aspirin and hydroxymethylacylfulvene analogs | GUTTAG ALVIN (US) | 2002-05-30 | — | — | US | disclosed |
| US-6368615-B1 | POLYMER OF UNSATURATED ESTER OF SALICYLIC ACID | GUTTAG ALVIN (US) | 2002-04-09 | — | — | US | disclosed |
| US-6037338-A | AND REDUCING RISK OF HEART ATTACKS | GUTTAG ALVIN (US) | 2000-03-14 | — | — | US | disclosed |
| US-5910511-A | ALTERNATIVE TO ASPIRIN WHICH HAS LESSER UNDESIRABLE SIDE EFFECTS | GUTTAG ALVIN (US) | 1999-06-08 | — | — | US | disclosed |
| US-5760261-A | ANTINFLAMMATORY AGENTS, ANTIPYRETICS, ANALGESICS; SIDE EFFECTREDUCTION | GUTTAG ALVIN (US) | 1998-06-02 | — | — | US | disclosed |
| US-5648084-A | Multiple dosage medicine drop bottle | GUTTAG ALVIN (US) | 1997-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065254-A1 | Ibuprofen-aspirin and hydroxymethylacylfulvene analogs | PTGES3, HPGDS, PTGES | KDM4E 653/4885HSD17B10 623/4885HPGD 25/4885 |
| US-20030008833-A1 | Ibuprofen-aspirin, hydroxymethylacylfulvene analogs and L-sugar illudin analogs | GALE, TPT1, HPSE | KDM4E 1066/4885HSD17B10 1828/4885HPGD 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.